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A safe and effective direct acting anti-hepatitis C virus (HCV) agent is still needed. In this 
study, human single chain variable fragments of antibody (scFvs) that bound to HCV 
NS3/4A protein were produced by phage display technology. The engineered scFvs 
were linked to nonaarginines (R9) for making them cell penetrable. HCV-RNA-transfected 
Huh7 cells treated with the transbodies produced from four different transformed E. coli 
clones had reduced HCV-RNA inside the cells and in the cell spent media, as well as 
fewer HCV foci in the cell monolayer compared to the transfected cells in culture medium 
alone. The transbodies-treated transfected cells also had up-expression of the genes 
coding for the host innate immune response, including TRIF, TRAF3, IRF3, IL-28B, and 
IFN-β. Computerized homology modeling and intermolecular docking predicted that the 
effective transbodies interacted with several critical residues of the NS3/4A protease, 
including those that form catalytic triads, oxyanion loop, and S1 and S6 pockets, as well 
as a zinc-binding site. Although insight into molecular mechanisms of the transbodies 
need further laboratory investigation, it can be deduced from the current data that the 
transbodies blocked the HCV NS3/4A protease activities, leading to the HCV replication 
inhibition and restoration of the virally suppressed host innate immunity. The engineered 
antibodies should be tested further for treatment of HCV infection either alone, in com-
bination with current therapeutics, or in a mixture with their cognates specific to other 
HCV proteins.
Keywords: cell-penetrating antibody (transbody), hepatitis c virus, innate immunity, phage display, ns3/4a 
protease, qrT-Pcr, single chain antibody
inTrODUcTiOn
Before 2011, patients with hepatitis C virus (HCV) infection were weekly injected with pegylated-
interferon-alpha combined with daily oral ribavirin (a nucleoside analog), which is a  standard-of-care 
(SOC). The treatment conferred high rate of sustained virologic response (SVR) against HCV of most 
genotypes by restoring the virally suppressed host innate immunity and restraining the viral load (1). 
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However, HCV strains of genotype 1 were relatively refractory to 
the SOC. Besides, the regimen is prolonged, stringent, and costly, 
as well as induces severe adverse effects, which are poorly toler-
ated by a significant fraction of the recipients. During the past 
decade, intense research has focused on development of direct 
acting anti-HCV agents (DAAs) that interfere with the functions 
of several HCV proteins. These are, for examples, inhibitors of 
NS3/4A protease (e.g., telaprevir, boceprevir, simeprevir, asunap-
revir, danoprevir, faldaprevir, paritaprevir); NS5B polymerase 
(e.g., sofosbuvir, dasabuvir); a protein important for membrane 
web formation, NS4B [e.g., substituted imidazo(1,2-a) pyrimi-
dines, clemizole, piperazinones]; a regulatory phosphoprotein of 
the viral replication complex, NS5A (e.g., ombitasvir, daclatasvir, 
ledipasvir, velpatasvir); or capsid protein (2–10). Also, drugs that 
inhibit HCV–host protein interaction have been tested (11, 12). 
Presently, several DAAs have received regulatory approval for 
clinical use, such as protease inhibitors (boceprevir, telaprevir, 
and semiprevir), polymerase inhibitor (sofosbuvir), and NS5A 
inhibitor (ledipasvir). Additional DAAs are in various stages of 
clinical development (9, 13). Many new drug regimens, when 
administered either singly, together with SOC, or in various 
combinations among themselves, conferred improved SVR rate 
compared with SOC (9, 13–16). However, the challenges that 
the new drugs are facing include complicated treatment proto-
cols, additional severe side effects, drug–drug interaction, and 
emergence of drug- and cross-drug-resistant HCV mutants. The 
new regimens are contraindicated for some groups of patients/
subjects (16–21). Thus, safe and effective DAAs are needed.
Passive immunization (administration of ready-made 
antibody) has been practiced for prevention/intervention and 
treatment of diseases since the late eighteenth century (called 
serum therapy/serotherapy at the time) (22). Nevertheless, the 
physicochemical properties of the plasma membrane impede 
accessibility of antibodies to their intracellular targets (such 
as proteins/enzymes of replicating virus). To circumvent this 
obstacle, several peptides called cell-penetrating peptides (CPPs) 
have been developed for delivering antibodies/antibody frag-
ments and a variety of other cargoes (proteins, drugs, nucleic 
acids, plasmids, and siRNAs) across the plasma membrane into 
cytosol and also to different subcellular compartments (23–27). 
Examples of the CPPs are protein transduction domains (such as 
penetratin, HIV-1 Tat peptide) (28), amphipathic peptides such 
as protein-rich motif (SAP) (29), and other CPP type, including 
nonaarginine (R9) and polylysine (30). In our laboratory, cell-
penetrable antibodies (transbodies) specific to viral proteins have 
been prepared by linking the antibody molecules to either pen-
etratin or R9. These fusion proteins readily entered mammalian 
cells and bound to their respective intracellular targets (31–35).
Usually, an antibody molecule uses several amino acids in the 
complementarity determining regions (CDRs) to interact with 
multiple residues/sites of the target, which makes it difficult for 
the pathogens to escape the antibody binding. On the contrary, 
pathogens may resist small molecular inhibitors through a 
single amino acid mutation (21). In this study, cell-penetrable 
human single chain antibody variable fragments (transbodies) 
to HCV protease that inhibit the viral replication and restore 
the host innate immune response were produced. It is envisaged 
that a right combination of cell-penetrable human/humanized 
antibodies that target pivotal enzymes of the HCV, i.e., helicase 
(31), polymerase (32, 33), and protease (34), a strategy similar 
to the precedent anti-HIV regimen, should be a novel anti-HCV 
remedy that is safe, genotype independent, and more tolerable to 
the viral mutation.
MaTerials anD MeThODs
recombinant hcV ns3/4a Fusion  
Protein Production
The recombinant NS3/4A protein (rNS3/4A) with the HCV-
inherent serine protease activity was produced from BL21 (DE3) 
E. coli carrying pET23b+-NS3/4A, as described previously (34). 
The fusion protein contained 180 amino acids of the N-terminal 
one-third of the NS3 of the genotype 3a HCV linked with resi-
dues 21–32 of the NS4A of the same genotype. The recombinant 
NS3/4A protein cleaved a fluorescent peptide substrate that 
contained nine amino acids at the protease cleavage site as deter-
mined by a continuous fluorescence resonance energy transfer 
(FRET) assay (34).
Mouse anti-ns3/4a Polyclonal antibody
The experiments received approval from the Siriraj Bio-safety Risk 
Management Taskforce (SI 2014-004). Three ICR mice (National 
Laboratory Animal Center, Mahidol University, Nakhonpathom, 
Thailand) were housed in a shoe-box typed cage under 12/12 
light/dark cycle at 23–25°C and 55–60% humidity. Feed and 
water were supplied ad  libitum. The animals were immunized 
intraperitoneally with three doses at 2-week intervals of 10 μg 
purified recombinant NS3/4A protein mixed with alum (Pierce, 
USA) at ratio 1:3. After the last booster, the mice were bled and 
their serum titers were assessed against the homologous antigen 
by indirect ELISA.
immunological Methods
Indirect ELISA was performed as described previously (33) 
using 1  μg of purified rNS3/4A protein in 100  μl of carbon-
ate–bicarbonate buffer, pH 9.6 to coat each well of an ELISA 
plate. Five percent skim milk in PBS (300  μl/well) was used 
for blocking the well surface before adding antibody prepara-
tions (e.g., serial dilutions of the mouse immune sera, HuscFv 
preparations) into appropriate wells. Antibody control was either 
normal mouse serum or lysate of original E. coli. Bovine serum 
albumin (BSA) served as control antigen and PBS as blank. After 
incubation, all wells were washed with the PBS containing 0.05% 
Tween-20 (PBST). Horseradish peroxidase (HRP)-conjugated 
anti-immunoglobulin isotype (Southern Biotech, Birmingham, 
AL, USA) and chromogenic substrate (KPL, Gaitherburg, MD, 
USA) were used for color development. The enzymatic reaction 
was stopped by adding 1% SDS. OD405nm of contents in all wells 
were determined against blank.
For SDS-PAGE and Western blot analysis (WB), polyacryla-
mide gel at a desired gel percentage cast in a Mini-PROTEAN-3® 
Cell System (Bio-Rad, Hercules, CA, USA) was used. Samples 
prepared in 6 × SDS gel reducing buffer were boiled for 10 min 
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before loading into the gel slots made in the 4% stacking gel. 
PageRuler® pre-stained protein ladders (Fermentas, Thermo 
Fisher Scientific, MA, USA) were included in one or two gel slots 
as molecular weight marker. Electrophoresis was carried out in 
Tris–glycine running buffer, pH 8.3, initially at 10  mA per gel 
until the bromphenol blue dye font reached the resolving gel; then 
the electricity was increased to 20 mA and continued until the dye 
font reached the lower gel edge. Separated proteins in the gel were 
either revealed by staining with Coomassie Brilliant Blue G-250 
dye or they were electroblotted onto nitrocellulose membrane 
(NC) for WB. For WB, the blotted NC was blocked either with 3% 
BSA or 5% skim milk in PBS. The blocked NC was then probed 
with antibody preparation; then the antigen–antibody reactive 
bands were revealed using alkaline phosphatase (AP)-labeled 
anti-isotype antibody and AP chromogenic substrate.
Phage clones That Bound to the rns3/4a 
Protein and the Phage Transformed E. coli 
clones
Phage clones bound to the rNS3/4A fusion protein were fished-out 
from a human scFv phage display library as described previously 
(33) using purified rNS3/4A (1 μg) as bait. The rNS3/4A-bound 
phages were put into HB2151 E. coli bacteria, and the bacteria 
were spread on a 2 × YT-AG plate. Direct colony PCR (36) was 
used to screen E. coli colonies that carried HuscFv coding genes 
(huscfvs). Lysates of huscfv-positive E. coli colonies grown in 
0.5 mM IPTG-conditioned broth were determined by Western 
blotting for the presence of the E-tagged-HuscFvs.
characterization of the Bacterially 
Derived-huscFvs
Spectrometrically standardized soluble HuscFvs in the lysates 
of transformed HB2151 E. coli clones were tested for binding to 
the rNS3/4A by indirect ELISA and Western blotting. Original 
HB2151 E. coli (HB) was used as background binding control in 
both assays. BSA served as control antigen in the indirect ELISA.
Diversity of the huscfvs sequences of the HB2151 E. coli clones 
were determined by subjecting the PCR amplified huscfvs to MvaI 
digestion followed by resolving the cut DNA products in 14% 
polyacrylamide gel containing 0.5% glycerol. Electrophoresis was 
carried out in TBE buffer at 20 mA per slab gel. The separated 
DNA bands were stained by ethidium bromide and the restric-
tion fragment length polymorphism (RFLP) was determined 
using a Bio Doc-ITTM Imaging System, UVP, USA. CDRs and 
their respective canonical immunoglobulin framework regions 
(FRs) of the sequenced huscfvs were predicted using an online 
Internatioanl ImMunoGeneTics (IMGT®) Information System.
generation of cell Penetrating huscFvs 
(Transbodies)
Because the antibodies must bind to the target inside the HCV-
infected cells, they were linked to nonaarginine (R9), which is a 
cell-penetrating peptide, as follow: the huscfvs were amplified from 
the pCANTAB5E phagemids using a Q5 High Fidelity DNA poly-
merase (Thermo Fisher Scientific). The specific primers were for-
ward-R9-huscfv-LIC: 5′-GGTTGGGAATTGCAACGTCGCCGT 
CGCTCGCCGTCGCCGTCGCCGTGCGGCCCAGCCCG 
GCC-3′ and reverse-E-tag-LIC: 5′-GGAGATGGGAAGTCATT 
AACGCGGTTCCAGCGGATCC-3′. The reaction mixture 
contained 15.75 μl sterile distilled water, 5.0 μl Q5 reaction buffer 
(5×), 0.5 μl dNTP mix (10 mM each), forward and reverse primers 
(10 μM in 1.25 μl each), 1.0 μl of huscfv-phagemid template (3 ng 
DNA template), and 0.25 unit of Q5 Hotstart DNA polymerase. 
The thermal cycles were first denaturation at 98°C, 30 s; 34 cycles 
of denaturation at 98°C for 30 s, annealing/extension at 69°C for 
10s, and final extension at 72°C, 5 min; and hold at 4°C, several 
min. The PCR product was stained with ethidium bromide, veri-
fied, and purified from agarose gel using DNA extraction kit (Jena 
Bioscience, Jena, Germany). The 5′- and 3′- overhangs of the 
R9-huscfv amplicons were generated by setting up the following 
reaction mixtures: 9 μl of sterile distilled water, 2 μl of 5× LIC 
buffer, 0.1 pmol of the purified PCR product, and 1 μl T4 DNA 
polymerase and dGTP. The reaction mixtures were kept at 25°C 
for 5 min and stopped by adding 0.6 μl of 0.5 M EDTA. Annealing 
of the DNA products with 15 base pairs (bp) 5′-overhang to the 
pLATE52 vector containing complementary overhang was per-
formed by mixing 1 μl of the vector and 60 ng (0.02 pmol) LIC 
ready vector (Thermo Fisher Scientific). The mixtures were kept 
at 25°C for 5 min before putting into JM109 E. coli by heat-shock 
method. The transformed E. coli clones carrying the recom-
binant pLATE52-R9-huscfv plasmids were screened by PCR 
using the pLATE52 specific primers, i.e., LIC forward sequence: 
5′-TAATACGACTCACTATAGGG-3′ and LIC reverse sequence: 
5′-GAGCGGATAACAATTTCACACAGG-3′. The PCR reaction 
mixture was: 12.7 μl sterile distilled water, 2 μl PCR buffer + KCl 
(10×), 1.2 μl 25 mM MgCl2, 2 μl dNTP mix (10 μM each), 1 μl 
(10 μM) each of LIC primers, and 0.5 unit of Taq polymerase.
The pLATE52-R9-huscfv were extracted from the PCR posi-
tive clones, purified, put in Rosetta™2 (DE3)-competent cells 
(Novagen, Schwalbach, Germany), and spread onto selective LB 
agar plates supplemented with 100 μg/ml ampicillin and 34 μg/
ml chloramphenicol (Calbiotech, Spring Valley, CA, USA) (LB-
AC agar). The sibling E. coli colonies grown on the agar plates 
were randomly picked and screened for the presence of the 
pLATE52-R9-huscfv plasmids by PCR using the pLATE52 prim-
ers. The Rosetta™2 (DE3) bacteria with the pLATE52-R9-huscfv 
plasmids were cultured in 0.5 mM IPTG-conditioned broth. The 
induced bacterial cells were collected and R9-HuscFvs in their 
homogenates were determined by SDS-PAGE and Western blot-
ting using anti-6× His as the R9-HuscFv-detection reagent. The 
clones that expressed the R9-HuscFvs (with 6× His and T7 tags at 
the N-terminal and E-tag at the C-terminal) were kept as stocks 
in 20% glycerol at −80°C until use.
large-scale Production, Purification, and 
refolding of the cell Penetrating huscFvs
The Rosetta™2 (DE3) E. coli clones carrying the pLATE52-R9-
huscfv were grown in 2× YT-AC broth at 37°C with shaking at 
250  rpm for 16 h. Ten milliliters of the overnight culture were 
inoculated into 250  ml of 2× YT-AC broth in a 2-liter flask 
and incubated with shaking aeration at 37°C until OD600nm was 
approximately 0.8–0.9 (~3 h). The culture was added with IPTG 
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(final concentration of 1  mM), incubated at 30°C for 6  h, and 
centrifuged at 5,000 × g at 4°C for 20 min. To prepare the bacterial 
inclusion bodies (IBs), each 2 g of the E. coli wet pellets were lysed 
with 10 ml of BugBuster™ protein extraction reagent (Novagen, 
Schwalbach, Germany) and 20 μl of Lysonase™ bioprocessing 
reagent (Novagen). The preparation was kept at 25°C on a rotator 
for 20 min and centrifuged at 8,000 × g at 4°C for 30 min. IB in 
the pellet was washed twice with Wash-100 reagent and once with 
Wash-114 reagent with shaking at high speed for 40 min and cen-
trifuged. The IB was then washed with Wash-Solvent reagent and 
Milli Q water on ice also with vigorous shaking and centrifuged.
For HuscFv refolding, 5 ml of buffer [50 mM CAPS, pH 11.0; 
0.3% (w/v) N-Lauryl sarcosine; and 1 mM DTT] were added to 
reconstitute 5 mg of purified IB and kept at 4°C for 16 h. After 
dissolving completely, the protein was loaded into the Slide-A-
Lyzer® 2K Dialysis Cassettes G2 (Thermo Fisher Scientific), and 
the cassette was subjected to dialysis against 750 ml of a refolding 
buffer (20  mM imidazole, pH 8.5, supplemented with 0.1  mM 
DTT) at 4°C with slow stirring. After 3 h, the buffer was changed 
to fresh refolding buffer, and the dialysis was continued for 16 h. 
The refolded protein was subsequently dialyzed against a dialysis 
buffer (20  mM imidazole without DTT) with slow stirring at 
4°C for 16 h. The preparation was filtered through a 0.2-μm low 
protein binding Acrodisc® Syringe Filter (Pall, NY, USA) and kept 
in 30°C water-bath for additional 2 h before adding with 60 mM 
trehalose. Protein concentration of the refolded HuscFvs was 
measured (Pierce® BCA Protein Assay), while quality and purity 
of the proteins were determined by SDS-PAGE and protein stain-
ing. The antibodies were tested for binding to the homologous 
antigen (rNS3/4A) by indirect ELISA.
cell Penetrating ability of the r9-huscFvs, 
Their intracellular Target Binding,  
and Toxicity
The experiments involving HCV of this study received approval 
from the Siriraj Bio-safety Risk Management Taskforce. The 
pJFH-1 (GenBank AB047639), which carried a full-length HCV 
genotype 2a cDNA, was used for production of HCV RNA, as 
described previously (32, 33). Briefly, the plasmid was cut with 
XbaI endonuclease and transcribed using a T7-transcription kit 
(MEGAscript®, Ambion, Foster City, CA, USA). Ten micrograms 
of JFH-1 RNA were put in Huh7 cells (4 × 106 cells) suspended in 
0.4 ml of reduced serum medium (Opti-MEM, Invitrogen, USA) 
by means of electroporation; complete DMEM containing 10% 
heat-inactivated fetal bovine serum (Hyclone, USA) and antibiot-
ics was immediately added to the electroporated cells, which were 
then distributed onto individual cover slips (2 ×  104  cells/slip) 
placed in wells of a 24-well tissue culture plate After incubating 
at 37°C in 5% CO2 incubator overnight and rinsed with sterile 
PBS, the cells were replenished with 500  μl complete DMEM 
containing 10 μg of individual R9-HuscFvs. After 1  h, culture 
supernatants were removed; the cells were washed with PBS, fixed 
with 1% Triton X-100, 30 min; blocked with 3% BSA; and washed. 
Rabbit anti-6× His polyclonal antibody (Abcam, Cambridge, 
UK) (1:500) was added to the cells and incubated at 37°C for 
1 h, washed, and 1:1000 mouse anti-NS3/4A polyclonal antibody 
was added. After 1 h, the cells were washed and added with goat 
anti-rabbit Alexa Flour 488 (1:500) and donkey anti-mouse Alexa 
Flour®647 (Abcam). DAPI (1:5000) (Invitrogen, Carlsbad, CA, 
USA) was used to stain nuclei. The preparations were kept at 
37°C for 1 h, and the stained cells were observed under a confocal 
microscope.
CytoTox96® non-radioactive cytotoxicity (lactate dehydro-
genase, LDH) assay kit (Promega, Madison, WI, USA) and 
Cell Titer-Glo® Luminescent Cell Viability Assay kit (Promega) 
were used for determining cytotoxicity of the R9-HuscFvs to 
Huh7 cells. The LDH release assay was performed as described 
previously (35). Huh7 monolayer in individual wells of a 96-well 
tissue culture plate (2 × 104 cells/well) were washed with sterile 
PBS, added with 25 μg of R9-HuscFvs in complete DMEM, and 
incubated for 24 h at 37°C in 5% CO2 atmosphere. Controls were 
cells in the medium alone (minimal/spontaneous release) and 
cells added with 10% SDS (maximal release) were included. After 
24  h, culture supernatants (triplicate wells of each treatment) 
were collected separately. Fifty microliters of culture fluid were 
mixed with the assay buffer provided with the kit and kept at 25°C 
for 30  min under light protection. The reactions were stopped 
by adding 1 M acetic acid, and OD490nm was determined. Percent 
cytotoxicity was (LDH release of test − spontaneous LDH release)/
(Maximal LDH release − spontaneous LDH release) × 100 (35). 
Percent cell viability was calculated by subtracting 100 with 
percent cytotoxicity.
For the Luminescent Cell Viability Assay that quantifies the 
number of viable cells based on the amounts of ATP released 
by metabolically active cells, Huh7 cells cultured in complete 
DMEM were seeded into wells of a 96-well opaque tissue culture 
plates (Corning) (2 × 104 cells/well). After incubating at 37°C in 
5% CO2 atmosphere for 24 h, the spent media were removed, and 
the tested cells were added with 25 μg of purified R9-HuscFvs in 
100 μl complete DMEM. Medium only was added to the control 
cells (negative control). After keeping at 37°C in 5% CO2 incuba-
tor for 48 h, the plate was brought to room temperature (25°C) 
for 30 min; the medium in each well was replaced with 100 μl 
of the Glo reagent, kept on an orbital shaker for 2 min, then at 
room temperature for 10 more min for luminescence stabiliza-
tion. The luminescence signal of each well was recorded using 
Synergy™ H1 Multi-mode Reader (BioTek®). Luminescence of 
the well containing medium only served as background lumi-
nescence. The percentage of cell viability was (Luminescence of 
test  −  Background luminescence)/(Luminescence of negative 
control − Background luminescence) × 100.
For in vivo toxicity testing of the R9-HuscFv, a protocol of Thai 
Pharmacopia was followed. Two groups of male BALB/c mice 
(6–8 weeks old) were used. Each mouse of group 1 (n = 5) was 
injected intraperitoneally with 25 μg of R9-HuscFv/g body weight 
in 200 μl buffer. This antibody dose is higher than those used 
for passive immunization of human (37). Three more booster 
doses were given on every alternate day. Control mice (group 2; 
n = 4) were injected with buffer alone. The animals were observed 
daily for any sign of morbidity, including ruffled hair, eye and 
nasal discharge, diarrhea, loss of appetite, and body temperature. 
Their body weights were determined also. Seven days post-last 
booster, all mice were bled and their sera were monitored for 
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some parameters of blood chemistry including liver enzymes 
(AP, aspartate aminotransferase, and alanine aminotransferase) 
and total bilirubin.
Transbody-mediated inhibition  
of the hcV replication
Huh7 cells transfected with JFH-1 RNA was prepared as above. 
Aliquots of the transfected cells (2 × 105 cells/well) were added 
to individual wells of a 12-well tissue culture plates and kept 
for 3 h at 37°C in 5% CO2 incubator. After washing with sterile 
PBS, the cells were added with 25 μg of purified R9-HuscFvs dis-
solved in complete DMEM. Negative and background inhibition 
controls were the infected cells added with medium alone and 
medium containing 25  μg of control R9-HuscFv, respectively. 
Positive inhibition controls were 100  units of pegylated (PEG) 
interferon +  250  μM ribavirin, 0.175  μM telaprevir (VX-950) 
(Selleckem, Houston, TX, USA), and PEG-interferon + 250 μM 
ribavirin + 0.175 μM telaprevir. After 5 more days of incubation, 
total RNAs were extracted from the cells and their spent media 
(Trizol™ reagent, Invitrogen). Amounts of HCV 5′ UTR in all 
samples were quantified by qRT-PCR (33). Alternatively, culture 
supernatants of the infected cells in all wells were removed, and 
the viral foci formed in the respective cell monolayer were enu-
merated after staining for the HCV core protein (33).
Quantitative real-time rT-Pcr
The qRT-PCR reaction mixture (12.5 μl) was prepared: 6.25 μl 
2× Brilliant II SYBR® Green qRT-PCR master mix, 0.5 μl each of 
the JFH-1 5′ UTR primers, 0.5 μl RT/RNS block enzyme, RNA 
template up to 4.75 μl (200–900 ng of standard RNA), and sterile 
DEPC-treated distilled water to 12.5 μl. The amplification was 
carried out using Mx3000P QPCR System (Agilent Technologies) 
at 42°C for 30 min, 55°C for 30 min, initial denaturation at 95°C 
for 10  min, and 40 cycles of 95°C for 30  s, 60°C for 30  s, and 
72°C for 30 s. To analyze the dissociation curve, a thermal profile 
of 95°C for 1 min, ramped down to 55°C for 45 s at a speed of 
0.5°C/s and ramped up to 95°C was carried out. Ct of 10-fold 
serially diluted pJFH-1 with full-length HCV genotype 2a cDNA 
insert, calculated 2.77 × 107 to 0.02 copy numbers, were used for 
constructing a standard curve. Log10 RNA copies/ml of sample 
was extrapolated from the standard curve. Data of one of the three 
independent and reproducible experiments are reported herein.
hcV Foci assay
Hepatitis C virus foci formed in the JFH-RNA-transfected Huh7 
cell monolayer after receiving different treatments were enumer-
ated (34). Briefly, the spent culture fluids of the transfected cells of 
all treatments were discarded. After washing, the cells were fixed 
with absolute methanol at 4°C, 15 min; blocked for 1 h with 10% 
BSA at 37°C; incubated with mouse anti-HCV core polyclonal 
antibody; washed; added with AP-conjugated-goat anti-mouse 
isotype; washed again; and added with AP chromogenic substrate 
(KPL). Untreated transfected cells and non-transfected (normal) 
cells were included in the experiments as negative inhibition 
(maximal number of HCV foci) and negative foci control, respec-
tively. Numbers of HCV foci in each well were counted under 
40× magnification using an inverted fluorescence microscope 
(NIS-Element D version 4.10.0.8310 W/camera, Ti-S Intensilight 
Ril NIS-D, Nikon, Japan).
response of the hcV-rna-transfected 
cells after Treatment with the  
Transbodies and controls
After treating the JFH-1 RNA-infected Huh7 cells with various 
R9-HuscFvs and controls (control R9-HuscFv, PEG-IFN + riba-
virin, telaprevir, PEG-IFN + ribavirin + telaprevir, and medium 
alone), expressions of innate immune response genes (amounts 
of mRNAs), including TRIF, TRAF3, IRF3, IL-28B, and IFNβ, 
were determined by qRT-PCR as described previously (34) using 
GAPDH mRNA for normalization.
computerized simulation for Predicting 
residues of the hcV ns3/4a Protein 
Bound by the huscFvs
Three-dimensional structure of NS3/4A (PDB ID-1A1R, 
RCSB database) was retrieved. Tertiary structures of HuscFvs 
were modeled by subjecting their amino acid sequences to the 
I-TASSER server (38). The I-TASSER-predicted models were 
subsequently refined and improved to their nearest native state 
(39, 40). Molecular docking between the NS3/4A 3D and the 
HuscFv models was performed by ClusPro2.0 server (41). Pymol 
software (The PyMOL Molecular Graphics System, version 
1.3r1 edu, Schrodinger, LLC) was used to build and visualize the 
protein complexes that formed the largest cluster size and the 
minimal local energy.
statistical analysis
Means and SDs of tests and controls were compared using 
unpaired t-test. p < 0.05 was considered significantly different.
resUlTs
Phage-transformed E. coli clones That 
Produced hcV ns3/4a-bound huscFvs 
and the huscFv characteristics
Fifty-two HB2151 E. coli bacteria infected with the rNS3/4A-
bound phages that were grown on the selective LB-A agar plate 
were checked for the presence of huscfvs, and 18 clones (34.6%) 
revealed the genes at about 1,000 bp (Figure 1A). After growing 
these E. coli clones under 0.5 mM IPTG-conditioned broth, lysates 
of 17 clones contained HuscFvs seen as bands at ~27–32  kDa 
(Figure  1B). The HuscFvs of nine phage-transformed E. coli 
clones (nos. 6, 10, 21, 25, 27, 30, 34, 41, and 43) gave significant 
ELISA signal above controls (Figure  1C) and bound to SDS-
PAGE separated-rNS3/4A by WB (Figure 1D). The nine clones 
revealed eight different huscfv patterns (eight RFLP types) after 
cutting with MvaI; clones no. 6, 10, 21, and 25 had patterns 
1–4, respectively; clones no. 27 and 30 had the same pattern 5, 
while clones no. 34, 41, and 43 showed patterns 6–8, respectively 
(Figure 1E). DNA sequences of four clones, i.e., 6, 10, 25, and 
34, had complete coding regions, i.e., sequences of four FRs and 
FigUre 1 | Preparation of E. coli clones that expressed ns3/4a-bound huscFvs.  
 (Continued)
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FigUre 2 | schematic diagram of the R9-huscfv Dna construct (a) which the Dna sequence coding for r9-huscFv was flanked with 6× His and T7 
tags at the 5′ end and e-tag at the 3′ end; the vh and vl sequences of the huscfv were linked by nucleotides coding for (g4s)3. PCR amplicons of 
R9-huscfvs contained in the pLATE52-R9-huscfv plasmid-transformed Rosetta™2 (DE3) E. coli clones (B); the PCR product was ~1,140 bp; lane M, GeneRuler™ 
1 kb DNA ladder; lanes 1–4, PCR amplicons of R9-huscfv-6, -10, -25, and -34, respectively; numbers at the left are DNA sizes in base pairs. Western blot patterns 
of homogenates of the four pLATE52-R9-huscfv plasmid-transformed Rosetta™2 (DE3) E. coli clones after growing under IPTG induction (c); the homogenates 
were subjected to SDS-PAGE and probed with anti-6× His antibody; the R9-HuscFvs were ~34 kDa. Purified R9-HuscFv-6, -10, -25, and -34 from the respective 
E. coli inclusion bodies (D).
Results of PCR for amplification of huscfvs using 52 E. coli bacteria infected with individual phages that bound to recombinant NS3/4A as templates; 18 clones 
(34.6%) revealed the huscfvs at about 1,000 base pairs (bp) (a). After growing the huscfv-positive clones under 0.5 mM IPTG induction, the bacterial lysates were 
checked for HuscFvs by Western blot analysis. Seventeen of the 18 clones produced the HuscFvs seen as bands at ~27–32 kDa (B). After standardizing 
spectrophotometrically, the HuscFvs were tested for their ability to bind to the NS3/4A by indirect ELISA. The antibodies produced by nine phage-transformed 
E. coli clones (nos. 6, 10, 21, 25, 27, 30, 34, 41, and 43) gave significant ELISA signal to the rNS3/4A above control antigen (BSA) and negative HuscFv contol (HB 
or lysate of original HB2151 E. coli) (c). Binding of the HuscFvs from the nine clones was verified by Western blotting. The HuscFvs were used to probe the 
SDS-PAGE-separated rNS3/4A, and all of them bound to the antigen seen as diffuse bands at ~26–32 kDa (lanes 1–9) (D); lane 10, positive binding control which 
the SDS-PAGE-separated rNS3/4A was probed with mouse anti-NS3/4A polyclonal antibodies. Lanes M of (B) and (D), protein marker; numbers at the left are 
protein molecular masses in kDa. Restriction fragment length polymorphism (RFLP) of the huscfvs of the clones (e). Lanes M of (a) and  (e), DNA marker; numbers 
at the left are DNA sizes in bp.
FigUre 1 | continued
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three CDRs of both VH and VL domains with linker nucleotides 
coding for (G4S)3 in between the domains. Therefore, these clones 
were selected for further experiments.
cell Penetrable huscFvs (transbodies) and 
Their cell Penetrating ability and Toxicity
The huscfvs of the clones 6, 10, 25, and 34 in the pCANTAB5E-
huscfv recombinant phagemids were subcloned into the 
pLATE52 plasmids downstream of the R9 gene, and the recom-
binant plasmids were put into the Rosetta™2 (DE3) E. coli. 
Figure  2A shows schematic diagram of the R9-HuscFv DNA 
construct. Examples of the PCR products amplified from the 
pLATE52-R9-huscfv-transformed Rosetta™2 (DE3) E. coli sib-
ling clones are shown in Figure 2B. The R9-HuscFvs with 6× His 
and T7 tags at the N-terminal and E-tag at the C-terminal were 
produced by growing the respective transformed E. coli clones 
under the 1 mM IPTG induction condition. All clones expressed 
the R9-HuscFv fusion antibodies at ~32–34  kDa (Figure  2C). 
Figure 2D shows SDS-PAGE-separated R9-HuscFvs after being 
purified and refolded. The purified transbodies retained the 
rNS3/4A binding activity in the indirect ELISA (data not shown).
Ability of the R9-HuscFvs to enter the HCV JFH-1 RNA-
transfected Huh7 cells and colocalized with the intracellular 
NS3/4A protein was determined by immunofluorescence assay 
and confocal microscopy. Representative result is shown in 
FigUre 3 | immunofluorescence staining and confocal microscopy for determining entry of r9-huscFv10 (as representative) into hcV JFh-1 
rna-transfected huh7 cells and the r9-huscFv binding to the intracellular ns3/4a. HCV JFH-1 RNA-transfected Huh7 cells were incubated with the 
R9-HuscFv then stained (see Materials and Methods). Cells stained with DAPI for localization of nuclei (blue) (a). Intracellular R9-HuscFv probed with rabbit anti-6× 
His tag followed by goat anti-rabbit immunoglobulin-Alexa Flour®488 (Green) (B). Bright field (c). Intracellular NS3/4A probed with mouse anti-NS3/4A followed by 
donkey anti-mouse immunoglobulin-Alexa Flour®647 (red) (D). Merged A, B, and D (e). The R9-HuscFv readily entered the HCV-infected cells and colocalized with 
the intracellular NS3/4A (orange).
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Figure  3. The intracellular R9-HuscFvs probed with rabbit 
 anti-6× His tag followed by goat anti-rabbit immunoglobulin-
Alexa Flour®488 gave green fluorescence, while the intracellular 
NS3/4A probed with mouse anti-NS3/4A followed by donkey 
anti-mouse immunoglobulin-Alexa Flour®647 appeared in red. 
The DAPI-stained nuclei are seen in blue. After merging, the 
R9-HuscFv and the NS3/4A were found to colocalize (orange).
Huh7 cells exposed to 25 μg of the respective R9-HuscFvs for 
24 h did not release different LDH amounts from cells in medium 
alone (spontaneous release). The percent calculated viability of the 
transbody-treated cells was not different from the non-antibody-
treated cells (Figure  4A). Likewise, percent cell viability after 
incubating with the R9-HuscFvs assessed using CellTiter-Glo 
luminescence assay were not different from the cells in culture 
medium alone (Figure 4B). Results indicate biocompatibility of 
the R9-HuscFvs with the mammalian cells.
None of the mice that received, individually, four doses of 
25 μg/g body weight of R9-HuscFv10 (representative) and buffer 
intraperitoneally on every alternate day showed any sign of 
morbidity (fever, hair ruffle, or diarrhea). They had normal activ-
ity and appetite and gained some weight (Figure 4C). Values of 
some parameters of the mouse blood chemistry at day 7 post-last 
booster are shown in Table S1 in Supplementary Material.
Transbody-mediated inhibition of the  
hcV replication
The HCV 5′ UTR copy numbers recovered from the 
 HCV-RNA-transfected Huh7 cells that had been exposed to 
the NS3/4A-bound-R9-HuscFv-6, -10, -25, and -34 are shown 
in Figure  5 in comparison with various controls (positive and 
negative inhibition controls). Among the R9-HuscFvs, the 
R9-HuscFv10 and R9-HuscFv6 were the most effective trans-
bodies in reducing the amount of the intracellular HCV RNA. 
Efficacies of all inhibitors and controls in reducing the intracel-
lular HCV RNA are statistically compared as shown in Table 1.
Amounts of HCV 5′ UTR RNA in culture supernatants of all 
groups of the treated cells are shown in Figure 6. The most effec-
tive R9-HuscFvs in reducing the HCV RNA in the transfected 
cell culture supernatants were R9-HuscFv10 and R9-HuscFv6. 
Statistical differences of the effectiveness among groups are 
shown in Table 2.
Results of the assay for determining the HCV foci in transfected 
cells treated with R9-HuscFvs and controls are shown in Figure 7. 
Statistical comparison among all treatment groups are shown in 
Table 3. Figure S1 in Supplementary Material shows appearance 
of the HCV foci in cells of individual treatment groups after 
staining with anti-HCV core protein as the primary antibody. The 
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FigUre 4 | Viability of the huh7 cells after treating with r9-huscFvs and controls as determined by lDh assay (a) and cellTiter-glo® luminescent 
assay (B). For (A), Huh7 cells were incubated with 25 μg of R9-HuscFv-6, -10, -25, or -34. LDH in the cell culture medium was detected 24 h after adding the 
antibodies or controls, i.e., cells in medium alone (minimal/spontaneous LDH release) and cells added with 10% SDS (maximal LDH release). The calculated percent 
viability of the transbodies-treated cells was not different from the spontaneous (minimal) release. For (B), Huh7 cells were incubated with 25 μg of R9-HuscFvs or 
medium for 48 h and percent cell viability were determined using the Cell Titer-Glo® Luminescent Cell Viability Assay kit. The R9-HuscFvs did not cause significant 
reduction of the cell viability compared with the cells cultured in the medium alone. Daily body weights of mice injected intraperitoneally (c) with R9-HuscFv10 (as 
representative; blue line) compared with control mice that were injected with buffer alone (red line); all mice gained some weights during 14 days of experiment and 
did not show any sign of morbidity. Some biochemical parameters of the mouse blood samples are shown in Table S1 in Supplementary Material.
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effectiveness of the transbodies and the controls in reducing the 
numbers of HCV foci in the transfected cells were conformed to 
the results of the 5′ UTR RNA expression assay determined by the 
qRT-PCR. The R9-HuscFv10 was highly effective.
response of the hcV-rna-transfected 
cells after Treatment with the Transbodies
Details of the fold change of mRNA expressions of the innate 
immune response genes, including TRIF, TRAF3, IRF3, IL-28B, 
TaBle 1 | statistical comparison of the results of the hcV 5′ UTr mrna copy numbers recovered from the hcV-rna-transfected huh7 cells that had 
been exposed to the ns3/4a-bound r9-huscFvs and various controls.
Treatment huscFv Positive inhibition control Medium
6 10 25 34 control Peg-
iFn + ribavirin
Telaprevir Peg-iFn + ribavirin +  
telaprevir
huscFv
6 NS p = 0.21 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.43 p < 0.05
10 p = 0.21 NS p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.64 p < 0.05
25 p < 0.05 p < 0.05 NS p = 0.39 p < 0.05 p < 0.05 p = 0.34 p < 0.05 p < 0.05
34 p < 0.05 p < 0.05 p = 0.39 NS P < 0.05 p = 0.23 p = 0.93 p < 0.05 p < 0.05
Control p < 0.05 p < 0.05 p < 0.05 p < 0.05 NS p < 0.05 p < 0.05 p < 0.05 p = 0.77
Positive inhibition control
PEG-IFN + ribavirin p < 0.05 p < 0.05 p < 0.05 p = 0.23 P < 0.05 NS p = 0.27 p < 0.05 p < 0.05
Telaprevir p < 0.05 p < 0.05 p = 0.34 p = 0.93 p < 0.05 p = 0.27 NS p < 0.05 p < 0.05
PEG-IFN + ribavirin + telaprevir p = 0.43 p = 0.64 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 NS p < 0.05
Medium p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.77 p < 0.05 p < 0.05 p < 0.05 NS
NS, not significantly different.
FigUre 5 | amounts of hcV 5′ UTr rna in the JFh-1 rna-transfected huh7 cells after treating with the r9-huscFv-6, -10, -25, and -34 in 
comparison with controls. Table 1 shows p values for statistical comparison among different treatments.
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and IFN-β, after various treatments in comparison with the 
non-transfected (normal) Huh7 cells cultured in the medium are 
shown in Table 4. The R9-HuscFv6 and R9-HuscFv10 restored 
expressions of all studied host innate immune response genes. 
The control transbody-exposed transfected cells and the trans-
fected cells maintained in medium alone had lower expressions of 
the genes than the non-transfected (normal) cells. At the condi-
tion and time of the experiments, TRAF3 and IL-28β mRNAs 
could not be rescued by the R9-HuscFv25 and R9-HuscFv34, 
respectively. All positive inhibitors, particularly the combined 
PEG-IFN-α + ribavirin + telaprevir effectively restored expres-
sions of all of the studied genes.
TaBle 2 | statistical comparison of the results of the hcV 5′ UTr copy numbers recovered from culture supernatants of the hcV-rna-transfected 
huh7 cells that had been treated with r9-huscFv-6, -10, -25, and -34 and various controls.
Treatment huscFv Positive inhibition control Medium
6 10 25 34 control Peg-
iFn + ribavirin
Telaprevir Peg-iFn + ribavirin +  
telaprevir
huscFv
6 NS p < 0.05 p < 0.05 p = 0.23 p < 0.05 p = 0.88 p = 0.47 p < 0.05 p < 0.05
10 p < 0.05 NS p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.71 p < 0.05
25 p < 0.05 p < 0.05 NS p < 0.05 p < 0.05 p = 0.24 p = 0.05 p < 0.05 p < 0.05
34 p = 0.23 p < 0.05 p < 0.05 NS P < 0.05 p = 0.29 p = 0.17 p < 0.05 p < 0.05
Control p < 0.05 p < 0.05 p < 0.05 p < 0.05 NS p < 0.05 p < 0.05 p < 0.05 p = 0.94
Positive inhibition control
PEG-IFN + ribavirin p = 0.88 p < 0.05 p < 0.05 p = 0.29 P < 0.05 NS p = 0.39 p < 0.05 p < 0.05
Telaprevir p = 0.47 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.39 NS p < 0.05 p < 0.05
PEG-
IFN + ribavirin + telaprevir
p < 0.05 p = 0.71 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 NS p < 0.05
Medium p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.94 p < 0.05 p < 0.05 p < 0.05 NS
NS, not significantly different.
FigUre 6 | amounts of hcV 5′ UTr rna in culture fluids after treating with the r9-huscFv-6, -10, -25 and -34 in comparison with controls. Table 2 
shows p values for statistical comparison among different treatments.
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homology Modeling and intermolecular 
Docking for Predicting the Presumptive 
residues of the hcV ns3/4a interacted 
with the huscFvs
The top 10 treading templates used to model the HuscFv6, 
HuscFv10, HuscFv25, and HuscFv34 by I-TASSER and the top 10 
identified structural analogs of the HuscFvs in the PDB are shown 
in Tables S2A,B–S5A,B in Supplementary Material, respectively. 
Table S6 in Supplementary Material gives details of the qualities 
of the I-TASSER-predicted HuscFv models used in this study. The 
ClusPro lowest local energies of interactions between the NS3/4A 
3D structure and the modeled HuscFv6, HuscFv10, HuscFv25, 
and HuscFv34 were −356, −428, −290, and −293  kcal/mol, 
TaBle 3 | statistical comparison of the results of the hcV foci assay among hcV-rna-transfected huh7 cells treated with r9-huscFvs and various 
controls.
Treatment huscFv Positive inhibition control Medium
6 10 25 34 control Peg-
iFn + ribavirin
Telaprevir Peg-iFn + ribavirin +  
telaprevir
huscFv
6 NS p < 0.05 p < 0.05 p = 0.20 p < 0.05 p = 0.99 p = 0.75 p < 0.05 p < 0.05
10 p < 0.05 NS p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.90 p < 0.05
25 p < 0.05 p < 0.05 NS p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05
34 p = 0.20 p < 0.05 p < 0.05 NS P < 0.05 p = 0.20 p = 0.31 p < 0.05 p < 0.05
Control p < 0.05 p < 0.05 p < 0.05 p < 0.05 NS p < 0.05 p < 0.05 p < 0.05 p = 0.61
Positive inhibition control
PEG-IFN + ribavirin p = 0.99 p < 0.05 p < 0.05 p = 0.20 P < 0.05 NS p = 0.77 p < 0.05 p < 0.05
Telaprevir p = 0.75 p < 0.05 p < 0.05 p = 0.31 p < 0.05 p = 0.77 NS p < 0.05 p < 0.05
PEG-
IFN + ribavirin + telaprevir
p < 0.05 p = 0.90 p < 0.05 p < 0.05 p < 0.05 p < 0.05 p < 0.05 NS p < 0.05
Medium p < 0.05 p < 0.05 p < 0.05 p < 0.05 p = 0.61 p < 0.05 p < 0.05 p < 0.05 NS
NS, not significantly different.
FigUre 7 | Foci of hcV in the hcV-rna-transfected huh7 cells after exposure to the r9-huscFv-6, -10, -25, and -34 in comparison with controls. 
Table 3 shows p values for statistical comparison among different treatments.
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respectively. Details of intermolecular docking, including 
the interactive residues of the NS3/4A/HCV polyprotein and 
motives and amino acids and domains of the HuscFvs as well 
as the interactive bonds between the two parties, are shown in 
Table 5 and Figures S2–S5 in Supplementary Material. Besides 
the molecular bonds in Table 5, the amino acid residues of the 
NS3/4A within 5 Å thresholds of van der Waals radii of HuscFvs 
are shown separately in Table 6.
The most effective HuscFv10 in inhibiting the HCV replication 
was found to form interface contact with many critical residues 
of the NS3/4A important for protease activity including H57 and 
D81 of the catalytic triad, Y56 and D79 near to the catalytic site, 
K136 and G137 of the oxyanion loop, and K20 of NS4A cofactor 
which is adjacent to the NS4A residues 21–34 that usually inter-
acts with the NS3 for enhancing the protease activity (Table 5B 
and Figure S2 in Supplementary Material). Table 6B shows the 
TaBle 4 | Fold change of innate immune response genes in hcV-rna-transfected human hepatic cells compared to non-transfected cells after treating 
with ns3/4a specific-r9-huscFvs and various controls.
gene Fold change of mrnas of innate immune response genes in hcV-rna-transfected cells treated with
r9-huscFv Peg-iFnα-
2a + ribavirin
Telaprevir Peg-iFnα-
2a + ribavirin + telaprevir
control 
r9-huscFv
Medium
6 10 25 34
TRIF 45.89↑ 49.52↑ 3.23↑ 1.25↑ 28.64↑ 10.78↑ 150.12↑ 1.18↓ 1.08↓
TRAF3 32.67↑ 83.87↑ 1.75↓ 1.97↑ 15.14↑ 11.96↑ 64.89↑ 1.23↓ 1.82↓
IRF3 22.78↑ 32.90↑ 3.71↑ 3.05↑ 8.69↑ 11.96↑ 26.09↑ 5.55↓ 1.11↓
IL-28B 15.67↑ 10.41↑ 1.89↑ 3.57↓ 22.16↑ 6.11↑ 34.06↑ 3.70↓ 2.00↓
IFNβ1 16.45↑ 51.98↑ 6.36↑ 4.66↑ 53.08↑ 18.90↑ 125.37↑ 1.64↓ 1.32↓
↑, fold increase; ↓, fold decrease.
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van de Waals forces that may contribute also to the HuscFv10-
target association.
The HuscFv6, which was also highly effective in HCV replication 
inhibition, did not interact with any residues of the catalytic triad 
(H57, D81, and S139), oxyanion loop (135LKGSS139), or residues 
C97, C99, C145, and H149 of the zinc binding site. Instead, center 
of target binding of this HuscFv6 was located at the basic triad, 
i.e., 117RRR119, and R123 of the NS3/4A β–B2 and β-C2 motives 
(Tables 5A and 6A and Figure S3 in Supplementary Material).
The HuscFv25, similar to the HuscFv6, interacted with the 
basic residues: R117, R119, and R123, although at the higher local 
energy than the HuscFv6 (Tables 5C and 6C and Figure S4 in 
Supplementary Material).
The HuscFv34 not only interacted with the 117RRR119 but also 
with the P146 and T/S147 in the zinc binding site of the protease 
(Tables 5D and 6D and Figure S5 in Supplementary Material).
DiscUssiOn
There is a need of an improved regimen/remedy for treatment 
of HCV infection. A novel DAA that we would like to offer for 
future development is the engineered cell-penetrating human/
humanized small antibody fragments that interfere with enzymes 
of the virus. The NS3/4A serine protease is pivotal for releasing 
mature NS4A, NS4B, NS5A, and NS5B from polyprotein (42) for 
the HCV replication, assembly, and egress. It also suppresses the 
host innate antiviral response.
During the early phase of infection, molecular signatures of 
intracellular viruses usually alarm the host pathogen recogni-
tion receptors (PRRs), including endosomal Toll-like receptors 
(TLRs), and cytosolic retinoic acid-inducible gene 1/helicard 
(RIG-1/Mda5) to activate various adaptor proteins, i.e., TRIF 
(Toll-IL-1 receptor domain-containing adaptor inducing IFN-β), 
Cardif/MAVS, and TRAFs (tumor necrosis factor-associated 
factors). These factors consequently activate kinases (TBK1 and 
IKKs) leading to phosphorylation and dimerization of interferon 
regulatory factor 3/7 (IRF3/7) transcription factor for production 
of innate interferons, including type-I IFN-β and type-III IFN-λ 
(IL-28/29) (43–45). The IFNs mediate autocrine and paracrine 
stimulation of the host cells through JAK/STAT signaling path-
ways leading to production of various antiviral factors, i.e., 2′, 
5′ OAS, PKR, MxA, and ISGs, as well as MHC class I molecules 
for cytotoxic lymphocyte activation (45). NS3/4A protein of the 
infecting HCV cleaves TRIF and Cardif/MAVS, binds to TBK1, 
and inhibits activation of IRF3 (46–48). Moreover, the protein 
has been implicated in malignant transformation (49–51). The 
NS3 N-terminal is known to interact with p53 (a tumor sup-
pressor) and inhibited apoptosis of NIH3T3 cells (51, 52). As 
such, interference with the HCV NS3/4A functions should lead 
to inhibition of the viral replication as well as restoration of the 
virally suppressed host innate immune response and might as 
well reduce the hepatocellular carcinoma incidence among the 
chronically infected subjects.
In this study, bacterially derived engineered human single 
chain antibodies that bound to active HCV NS3/4A protein were 
generated. Because the antibody target is located intracellularly, 
the antibodies were made into cell penetrable molecules by linking 
their coding sequences to nonaarginine (R9) nucleotides using 
a ligase-independent cloning (LIC) method. The R9-HuscFvs 
were readily purified from the IBs of four E. coli clones (nos. 6, 
10, 25, and 34) carrying the R9-huscfv plasmids and successfully 
refolded using the protocol adapted from (53) and instruction 
manual of the Protein Refolding Kit of Novagen. The R9-HuscFvs 
retained their binding to the rNS3/4A as the parental HuscFvs 
(data not shown) indicating the native refolding of the antibod-
ies. They readily entered the human hepatic cells (Huh7) and 
bound to the intracellular target. They did not cause significant 
LDH leakage from the cocultured human hepatic cells compared 
with the cells in the medium alone indicating compatibility of 
the antibody preparations with the mammalian cells at the dose 
that was tested. Safety of the transbodies was also demonstrated 
in mice after injecting them intraperitoneally (followed the Thai 
Pharmacopia) at the dose that was relatively high (25 μg/g body 
weight) for passive immunization in humans (37).
There were significant reductions of the HCV 5′UTR RNA 
in the Huh7 cells transfected with JFH-RNA and in the cell 
culture supernatants after treating with the R9-HuscFvs (albeit 
different degrees of effectiveness among the transbodies from 
different E. coli clones). The results of foci assay were conformed 
to the RNA quantification. The most effective transbodies were 
R9-HuscFv10 and R9-HuscFv6. These transbodies could readily 
restore expressions of all of the studied innate immune response 
genes of the HCV-RNA-transfected cells. Taken all together, the 
results indicate that the transbodies-mediated viral replication 
inhibition and host innate immune response restoration via the 
NS3/4A protease interference.
TaBle 5 | Presumptive residues and regions of the ns3/4a and polyprotein of hcV bound by specific huscFvs.
hcV protein huscFv intermolecular bond
ns3 residue Polyprotein residue Motif (-ves) amino acid Domain
a. huscFv6
R117 R1149 β-B2 F52 VH-CDR2 Cation-π
Y102 VH-CDR3 H-bond
R118 R1150 β-B2 Y102 VH-CDR3 CH-π
R119 R1151 Between β-B2 and β-C2 D33 VH-CDR1 Salt-bridge
S57 VH-CDR2 H-bond
D121 D1153 Between β-B2 and β-C2 Y166 VL-CDR1 H-bond
S122 S1154 Between β-B2 and β-C2 S227 VL-CDR3 H-bond
F228 VL-CDR3 H-bond
R123 R1155 Between β-B2 and β-C2 E59 VH-CDR2 H-bond
E62 VH-CDR2 Salt-bridge
F228 VH-CDR3 NH-π
K165 K1197 β-F2 E55 VH-CDR2 Salt-bridge
S57 VH-CDR2 H-bond
P171 P1203 β-F2 Y226 VH-CDR3 CH-π
E173 E1205 α-helix c Y226 VL-CDR3 H-bond
B. huscFv10
T40 T1071 Between β-B1 and β-C1 E55 VH-CDR2 H-bond
Y56 Y1088 α-helix a Y227 LCDR3 π–π stacking
H57 H1089 α-helix a (catalytic triad) Y165 LCDR1 H-bond
D79 D1111 Between β-E1 and β-F1 S162 LCDR1 Water bridge
R164 LCDR1 H-bond
S225 LCDR3 H-bond
D81 D1113 Between β-E1 and β-F1 (catalytic triad) Y165 LCDR1 H-bond
K136 K1168 Between α-helix b and β-D2 (oxyanion loop) S31 VH-CDR3 H-bond
Y101 VH-CDR3 Cation-π
G137 G1169 Between α-helix b and β-D2 (oxyanion loop) Y102 VL-CDR1 H-bond
R155 R1187 β-E2 Y165 VH-CDR H-bond
D183 VL-CDR2 Salt-bridge
A157 A1189 β-E2 Y105 VH-CDR3 H-bond
NS4A K20 K1677 Close to the first residue of NS4A cofactor peptide that 
binds to NS3 for enhancing the protease activity
T58 VH-CDR2 H-bond
E59 VH-CDR2 Salt-bridge
c. huscFv25
D103 D1135 β-A2 R31 VH-CDR1 Salt-bridge
R117 R1149 β-B2 F101 VH-CDR3 NH-π
R119 R1151 Between β-B2 and β-C2 R50 VH-CDR2 Water bridge
E99 VH-CDR3 Salt-bridge
F101 VH-CDR3 H-bond
Y168 VL-CDR2 H-bond
Y232 VL-CDR3 H-bond
D121 D1153 Between β-B2 and β-C2 D164 VL-CDR1 H-bond
S122 S1154 Between β-B2 and β-C2 D164 VL-CDR1 H-bond
R123 R1155 Between β-B2 and β-C2 S163 VL-CDR1 H-bond
D164 VL-CDR1 H-bond
S125 S1157 β-C2 R50 VH-CDR2 Water bridge
L127 L1159 β-C2 W33 VH-CDR1 CH-π
T52 VL-CDR2 H-bond
K165 K1197 β-F2 D57 VL-CDR2 Water bridge
D59 VL-CDR2 Salt-bridge
Y60 VL-CDR2 H-bond
W230 VL-CDR3 CH-π
D. huscFv34
S102 S1134 Between β-F1 and β-A2 D57 VH-CDR1 H-bond
D103 D1135 β-A2 D57 VH-CDR2 H-bond
R117 R1149 β-B2 T58 VH-CDR2 H-bond
D59 VH-CDR2 H-bond
R118 R1150 β-B2 W50 VH-CDR2 CH-π
R119 R1151 Between β-B2 and β-C2 D59 VH-CDR2 Salt-bridge
D121 D1153 Between β-B2 and β-C2 S101 VH-CDR3 H-bond
D182 VH-CDR2 Water bridge
R223 VL-CDR3 H-bond
(Continued)
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hcV protein huscFv intermolecular bond
ns3 residue Polyprotein residue Motif (-ves) amino acid Domain
S122 S1154 Between β-B2 and β-C2 R233 VL-CDR3 H-bond
P146 P1178 Between β-D2 and β-E2 (inside zinc binding site) Y54 VH-CDR2 CH-π
T147 T1179 Between β-D2 and β-E2 (inside zinc binding site) Y54 VH-CDR2 CH-π
E173 E1205 α-helix c K103 VH-CDR3 H-bond
TaBle 6 | amino acid residues of ns3 within 5 Å threshold of van der 
Waals radii of huscFvs in Table 2.
hcV protein
ns3 residue(s) ns3 motif (-ves)
a. huscFv6
D79 Between β-E1 and β-F1
G100, S101, S102 Near the zinc-binding site (C99)
D103 β-A2
G120 Between β-B2 and β-C2
G124, S125, L126, L127 β-C2
R155, V158 β-E2
A166, D168, D169 β-F2
N174, E176, T177, R178 α-helix c
R155, V158 β-E2
A166, D168, D169 β-F2
N174, E176, T177, R178 α-helix c
B. huscFv10
L13 Between β-A0 and α-helix 0
I17 α-helix 0
A39, Q41 Between β-A1 and β-B1
T42, F43 β-B1
V55 β-C1
G58, A59 α-helix a (near the catalytic site, H57)
G60, T61, R62 Between α-helix a and β-E1
V78, Q80 Between β-E1 and β-F1 (near catalytic site, D81)
R123 Between β-B2 and β-C2 (S6 pocket)
I132, S133, L135 α-helix b; L135 is at the S1 pocket
S138 Oxyanion loop
S139 Catalytic triad
F154, A156, V158, C159 β-E2 (F154 is at the S1 pocket)
T160, R161 Between β-E2 and β-F2
A164, D168 β-F2
c. huscFv25
S101 Near the zinc binding site (C99)
Y105 β-A2
P115, R118 β-B2
G120 Between β-B2 and β-C2
G124, L126, S128, P129 β-C2
P146 Near the zinc binding site (C145, H149)
V158 β-E2
T160, R161, V163 Between β-E2 and β-F2
A166 β-F2
D. huscFv34
D79, Q80 Between β-E1 and β-F1 (near catalytic site, D81)
C97 Zinc-binding site
T98 Between zinc-binding site (C97, C99)
C99 Zinc-binding site
G100, S101 Near zinc-binding site
G120, R123 Between β-B2 and β-C2 (R123 is at the S6 pocket)
S125 β-C2
C145 Zinc-binding site
P171 β-F2
V172, N174, T177 α-helix c
R18 Near α-helix c
TaBle 5 | continued
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Presumptive residues of the NS3/4A interacted with the 
HuscFvs were determined by means of computerized homology 
modeling and intermolecular docking. The lowest local energy 
of interaction between the HuscFv10 (which was most effective 
in inhibiting the HCV replication and in restoration of the host 
innate gene expressions) and the NS3/4A was −428  kcal/mol, 
indicating relatively higher affinity on the target binding of this 
antibody than the other three antibodies. The predictive residues 
of the NS3/4A protease interacted by the HuscFv10 included 
several residues critical for the protease activity, i.e., H57 and 
D81 of the catalytic triads and K136 and G137 of the oxyanion 
loop (54, 55). Binding of the antibody to the H57 and D81 should 
inhibit deprotonation of the S139 and, thus, failure of the S139 to 
mediate a nucleophilic attack of the carbonyl carbon of the scissile 
bond to form a tetrahedral intermediate containing an oxyanion; 
therefore, the proteolytic cleavage should not be complete, and, 
hence, no release of the N- and C-peptide products from the 
polyprotein (56). The HuscFv10 might as well disturb the func-
tion of the oxyanion loop by docking on the K136 and G137. 
Moreover, binding of the antibody to the NS4A K20 might as well 
interfere with the non-covalent interaction between the cofactor 
(residues 21–34 of NS4A) to the NS3; thus, impaired the cofactor 
enhancement of the protease activity. Besides, van de Waals force 
formed by HuscFv10 and several residues of NS3/4A molecule 
(Table 6) might have additional negative impact on the protease 
activity. Possibly by causing steric hindrance of the oxyanion hole 
via the S138, the S1 pocket through interactive atoms at the L135, 
F154 and nearby residues, i.e., A156, V158, and C159 (54, 55), 
and the S6 pocket by means of R123 which is one of the positively 
charged residues of the S6 that usually interact with the P6 and 
P5 residues (56, 57).
The HuscFv6 was as effective as the HuscFv10 in inhibiting the 
HCV replication. The antibody readily restored the host innate 
immune response genes from the HCV suppression as did the 
R9-HuscFv10. From computerized simulation, the lowest local 
binding energy of this antibody to the NS3/4A was as low as 
−356  kcal/mol. However, computerized simulation indicated 
that the HuscFv6 did not dock on any residues of the catalytic 
triad, oxyanion hole, or zinc biding site. Instead, the center of 
interaction of this antibody with the target was at the basic patch 
of the NS3 protein formed by R117, R118, and R119. Although 
the role of this cationic patch has not been elucidated, it is likely 
that residues in this region might form electrostatic interaction 
with certain negatively charged surface, such as viral RNA. 
This interaction might mediate pivotal, yet unraveled, activity 
of the HCV NS3. Binding of the R9-HuscFv6 to these residues 
might interfere with the activity. Besides, the positively charged 
residues R123 and K165 of the NS3/4A S6 pocket are believed to 
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interact with acidic residues at the P6, and sometimes the P5 also 
(57, 58); blocking of the R123 and K165 by CDR1 and CDR2 of 
the R9-HuscFv6 VL domain (Table 2) might interfere with the 
substrate binding of the protease. The HuscFv6 was predicted 
to form interactive atoms of van de Waals radii with multiple 
residues of the target (Table 3) that might also interfere with the 
NS3/4A activity by steric hindrance.
The HuscFv25 was the least effective transbody among the 
four in inhibiting the HCV replication. Computerized intermo-
lecular docking revealed that the antibody also interacted with 
the protease basic patch (R117, R118, and R119) and S6 pocket 
residues (R123 and K165) similar to the HuscFv6. However, the 
local energy that required for binding of this antibody to the tar-
get (−290 kcal/mol) was higher than that of the HuscFv6, which 
might explain the lower effectiveness of the HuscFv25.
The HuscFv34 interacted with residues of the zinc binding site 
(C97, C99, C145, P146, and T147), which might cause improper 
folding of the NS3 and, therefore, deficient in the protease activity 
(59, 60). The antibody also docked on the NS3 basic patch and, 
thus, might interfere with the important, but still unknown, activ-
ity of the NS3 protein.
In conclusion, bacterially derived cell-penetrating human 
single chain antibodies specific to NS3/4A protein of HCV 
produced in this study inhibited replication of the heteologous 
HCV (genotype 2a of the pJFH-1) in human hepatic cells and 
restored expressions of the virally suppressed host innate immune 
response genes. They were not toxic to human cells and mice. The 
transbodies have potential for developing and testing further for 
anti-HCV activity, either alone, in combination with the approved 
HCV therapeutics, or in a mixture with their cognate specific to 
other HCV proteins.
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